Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

DocGo Q3 2026 Results: Net Loss of $16.6M, Loss Narrows

DocGo Inc. reported a net loss of $18.3 million for the quarter ended September 30, 2026, on revenues of $73.4 million, compared to a net loss of $29.7 million on revenues of $70.8 million in the prior year period. The company's cash position decreased significantly from $51.0 million at year-end 2025 to $19.1 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue73.470.8
Profit before tax-18.2-43.2
Net income-16.6-27.8
EPS (diluted, $ a share)$-0.17$-0.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+3.7%
Operating margin-23.5%
Source

10-Q filed with the SEC, NASDAQ: DCGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

DocGo Inc.: key numbers

Share price
$0.1899Close, Nov 16
Market cap
$18.8M
Shares outstanding
98.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Health ServicesSIC 8000

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from DocGo Inc.

All →
5:04 PM ET 8-K
Executive Compensation

DocGo Executive Compensation

DocGo Inc. entered into a Transition Services and Separation Agreement with CEO Lee Bienstock, who will step down on March 31, 2027. During the transition period, Bienstock will receive a monthly salary of $90,000 and accelerated monthly equity vesting, followed by a $785,000 severance payment. The company is currently conducting a search for a successor CEO as Bienstock's original employment agreement was set to expire at the end of 2026.

Counterparty
Lee Bienstock
Term
Jan 1, 2027 - Mar 31, 2027
4:08 PM ET 8-K
Financial Results

DocGo Financial Results

DocGo reported Q3 2026 revenue of $73.4 million, a slight increase from $70.8 million in the prior year period, driven by record volumes in US medical transportation and phlebotomy. The company narrowed its net loss to $18.1 million and saw GAAP gross margin improve significantly to 29.7% due to profitability initiatives. Additionally, the Board has initiated a search for a new CEO as Lee Bienstock's contract expires at year-end, though he will remain through at least March 2027 to ensure a transition.

Term
Q3 2026
6:33 AM ET 8-K
Loan & Debt

DocGo $102M Debt Financing with Perceptive Credit Holdings IV, LP

DocGo Inc. and its subsidiary Ambulnz entered into an Amended and Restated Credit Agreement providing for up to $102 million in term loans, including $52 million in existing debt and $50 million in new and delayed draw facilities. The financing is structured to support the company's pending acquisition of Hicuity Health, Inc., with certain tranches funding upon the merger's closing.

Value
$102M
Counterparty
Perceptive Credit Holdings IV, LP
Term
through Dec 2029

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.